Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 9/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.50 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | CTH | P32929 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753656 | 1.00 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL4382591 | 1.00 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL783293 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL29420113 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL30094126 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL783292 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL8685653 | 0.77 | MAPT (0.64) | RRM2KDM4E | |
| SCHEMBL6261110 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTHNCOA1NCOA3 | |
| SCHEMBL6261112 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTHNCOA1NCOA3 | |
| SCHEMBL534248 | 0.75 | TOP2A (0.68) | RRM2RRM1RRM2BCISD1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984932-A4 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS INC (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0988285-A4 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS INC (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0988285-A1 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | Vion Pharmaceuticals, Inc. (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0984932-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | Vion Pharmaceuticals, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5869676-A | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998051669-A1 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051670-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-5767134-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |